Table 5.
Multivariate analysis of outcomes: propensity score matched data
| Grade 2-4 acute GVHD | N | HR (95% CI) | Overall p-value |
|---|---|---|---|
| MAC | 182 | 1 | 0.37 |
| RIC/NMA | 156 | 0.86 (0.62-1.20) | |
| Grade 3-4 acute GVHD | N | HR (95% CI) | Overall p-value |
| MAC | 182 | 1 | 0.02 |
| RIC/NMA | 156 | 0.49 (0.26-0.91) | |
| Chronic GVHD | N | HR (95% CI) | Overall p-value |
| MAC | 190 | 1 | 0.45 |
| RIC/NMA | 166 | 1.12 (0.83-1.51) | |
| Non-relapse mortality | N | HR (95% CI) | Overall p-value |
| MAC | 190 | 1 | 0.79 |
| RIC/NMA | 166 | 0.94 (0.58-1.50) | |
| Progression/relapse | N | HR (95% CI) | Overall p-value |
| MAC | 190 | 1 | 0.48 |
| RIC/NMA | 166 | 1.14 (0.80-1.62) | |
| Progression free survival | N | HR (95% CI) | Overall p-value |
| MAC | 190 | 1 | 0.87 |
| RIC/NMA | 166 | 1.02 (0.77-1.35) | |
| Overall Survival | N | HR (95% CI) | Overall p-value |
| MAC | 192 | 1 | 0.96 |
| RIC/NMA | 168 | 0.99 (0.72-1.36) |
Abbreviations: GVHD, graft versus host disease; HR, hazard ratio; MAC, myeloablative conditioning; NMA, non-myeloablative; NRM, non-relapse mortality; RIC, reduced intensity conditioning.